Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center
Articles by Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center
Addressing Treatment Gaps in HER2+ MBC
ByVolkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf ,Carmen Criscitiello, MD, PhD,Giuseppe Curigliano, MD, PhD,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.
Optimizing Therapy in HER2+ MBC Across the Globe
ByVolkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf ,Giuseppe Curigliano, MD, PhD,Carmen Criscitiello, MD, PhD,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.
A global perspective pertaining to how to best sequence therapies used to treat HER2+ metastatic breast cancer based on treatment advances and data presented on at ESMO 2021.
Expectations as to where antibody-drug conjugates in the pipeline will fit into HER2-positive metastatic breast cancer treatment algorithms.
Recent advances in the characterization and treatment of patients with HER2-positive metastatic breast cancer and brain metastases.
Therapeutic Advances in Prophylaxis Against CIN
ByHope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,William J. Gradishar, MD, Northwestern University,Rita Nanda, MD, The University of Chicago Medicine,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.
CIN: Adopting SIMBA Therapy Into Clinical Practice
ByHope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,William J. Gradishar, MD, Northwestern University,Rita Nanda, MD, The University of Chicago Medicine,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center A panel of oncologists react to their interest in using plinabulin as prophylaxis against chemotherapy-induced neutropenia in future clinical practice.
Implications for treating patients with solid tumor cancers with plinabulin based on quality-of-life data and results demonstrated by the PROTECTIVE-2 trial.
Subgroup analyses of the DESTINY-Breast03 study evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer.
CIN: Takeaways From the PROTECTIVE-1 Study
ByHope S. Rugo, MD,Rita Nanda, MD, The University of Chicago Medicine,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,William J. Gradishar, MD, Northwestern University An overview of the design and results of the PROTECTIVE-1 study of plinabulin versus pegfilgrastim in patients with solid tumors receiving docetaxel myelosuppressive chemotherapy.
Considerations regarding the potential to prevent chemotherapy-induced neutropenia with newer therapeutic strategies as well as changes to treatment dosages.
CIN Prophylaxis and Bone Pain
ByHope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,William J. Gradishar, MD, Northwestern University,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Rita Nanda, MD, The University of Chicago Medicine Recommendations regarding how to best manage patients who experience bone pain from chemotherapy-induced neutropenia prophylaxis with growth factor support.
A global perspective regarding standards of care for treating HER2-positive metastatic breast cancer in earlier treatment settings.
Global Trends in HER2+ MBC
ByVolkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf ,Carmen Criscitiello, MD, PhD,Giuseppe Curigliano, MD, PhD,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.
Breast oncologists discuss how they weigh the efficacy of anticancer treatment with the possibility of a treatment-related adverse event, like chemotherapy-induced neutropenia.
Managing CIN in Patients With Breast Cancer
ByHope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Rita Nanda, MD, The University of Chicago Medicine,William J. Gradishar, MD, Northwestern University Preventive therapies and factors that impact how to best mitigate chemotherapy-induced neutropenia in patients with breast cancer.
Advantages, in terms of safety and efficacy, of granulocyte colony-stimulating factors used as prophylaxis against chemotherapy-induced neutropenia.
G-CSFs for Chemotherapy-Induced Neutropenia
ByHope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,William J. Gradishar, MD, Northwestern University,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Rita Nanda, MD, The University of Chicago Medicine Breast oncologists react to the availability of granulocyte colony-stimulating factors, used as prophylaxis against chemotherapy-induced neutropenia.
Current recommendations by the National Comprehensive Cancer Network on chemotherapy-induced neutropenia prophylaxis, with special considerations for managing patients with cancer during COVID-19.
Notable ASCO Trial Updates
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology 
HER2+ MBC Adverse-Event Management
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology 
After Progression on PIK3CAi Therapy: MTOR Inhibition
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology 
Significance of PIK3CA Mutation in HR+ Breast Cancer
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology 
Mechanisms of Resistance to CDK4/6 Inhibitors
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology 
CDK4/6 Meta-Analysis Data
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology 
CDK4/6 Clinical Trial Survival Data Impact
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology 
CDK4/6 Inhibition in HR+ Metastatic Breast Cancer
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology 
Next-Generation Sequencing: Triple Negative Breast Cancer
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology 
Phase 3 ASCENT Regimen Accelerated Approval
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology 
SWOG S1416 and TBCRC 048 Phase 2 Trial Overviews
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology
CDK4/6 Clinical Trial Survival Data Impact
ASCO New Data: PARP Inhibitors
Identifying Drug-Induced ILD
Educational Tools for Possible Drug-Induced ILD
HER2+ MBC Adverse-Event Management
Use of Antibody Drug Conjugates and Potential for ILD